{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:32:29Z","timestamp":1786649549936,"version":"build-2736575974"},"reference-count":13,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T00:00:00Z","timestamp":1748390400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.4103\/ijo.ijo_1897_24","type":"journal-article","created":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T11:03:22Z","timestamp":1748430202000},"page":"921-923","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Brolucizumab results and adverse visual outcomes study: A single-center real-world Indian experience"],"prefix":"10.4103","volume":"73","author":[{"given":"Ramesh","family":"Venkatesh","sequence":"first","affiliation":[{"name":"Department of Retina and Vitreous, Narayana Nethralaya, Rajaji Nagar, Bengaluru, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupal","family":"Kathare","sequence":"additional","affiliation":[{"name":"Department of Retina and Vitreous, Narayana Nethralaya, Rajaji Nagar, Bengaluru, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaitra","family":"Jayadev","sequence":"additional","affiliation":[{"name":"Department of Retina and Vitreous, Narayana Nethralaya, Rajaji Nagar, Bengaluru, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishma","family":"Prabhu","sequence":"additional","affiliation":[{"name":"Department of Retina and Vitreous, Narayana Nethralaya, Rajaji Nagar, Bengaluru, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santosh Gopi Krishna","family":"Gadde","sequence":"additional","affiliation":[{"name":"Department of Retina and Vitreous, Narayana Nethralaya, Rajaji Nagar, Bengaluru, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naresh Kumar","family":"Yadav","sequence":"additional","affiliation":[{"name":"Department of Retina and Vitreous, Narayana Nethralaya, Rajaji Nagar, Bengaluru, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,5,28]]},"reference":[{"key":"R1-20260422","doi-asserted-by":"crossref","first-page":"5879","DOI":"10.1073\/pnas.85.16.5879","article-title":"Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli","volume":"85","author":"Huston","year":"1988","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R2-20260422","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2012\/980250","article-title":"scFv antibody: Principles and clinical application","volume":"2012","author":"Ahmad","year":"2012","journal-title":"Clin Dev Immunol"},{"key":"R3-20260422","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1093\/protein\/gzq028","article-title":"Stability engineering of scFvs for the development of bispecific and multivalent antibodies","volume":"23","author":"Miller","year":"2010","journal-title":"Protein Eng Des Sel"},{"key":"R4-20260422","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/s41433-019-0583-z","article-title":"Brolucizimab\u2014leading an era of structural revolution for long-term VEGF suppression","volume":"34","author":"Sharma","year":"2020","journal-title":"Eye"},{"key":"R7-20260422","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1097\/IAE.0000000000004009","article-title":"Incidence and risk factors of intraocular inflammation after brolucizumab treatment in Japan: A multicenter age-related macular degeneration study","volume":"44","author":"Inoda","year":"2024","journal-title":"Retina"},{"key":"R8-20260422","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.ophtha.2020.11.011","article-title":"Risk of inflammation, retinal vasculitis, and retinal occlusion\u2013related events with brolucizumab","volume":"128","author":"Mon\u00e9s","year":"2021","journal-title":"Ophthalmology"},{"key":"R9-20260422","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1097\/IAE.0000000000003769","article-title":"Retinal vasculitis or vascular occlusion after brolucizumab for neovascular age-related macular degeneration: A systematic review of real-world evidence","volume":"43","author":"Wykoff","year":"2023","journal-title":"Retina"},{"key":"R10-20260422","doi-asserted-by":"crossref","first-page":"698","DOI":"10.4103\/ijo.IJO_295_22","article-title":"Brolucizumab-induced retinal vasculitis \u2013 An Indian perspective","volume":"2","author":"Brar","year":"2022","journal-title":"Indian J Ophthalmol Case Rep"},{"key":"R11-20260422","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.4103\/IJO.IJO_2973_23","article-title":"Brolucizumab-associated intraocular inflammation in Indian patients by VRSI study group","volume":"72","author":"Agarwal","year":"2024","journal-title":"Indian J Ophthalmol"},{"key":"R12-20260422","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1167\/iovs.65.1.8","article-title":"Factors associated with intraocular inflammation in neovascular age-related macular degeneration patients treated with brolucizumab","volume":"65","author":"Hashimoto","year":"2024","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R14-20260422","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ophtha.2020.06.028","article-title":"HAWK and HARRIER: Ninety-six-week outcomes from the phase 3 trials of brolucizumab for neovascular age-related macular degeneration","volume":"128","author":"Dugel","year":"2021","journal-title":"Ophthalmology"},{"key":"R15-20260422","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ajo.2023.07.012","article-title":"KESTREL and KITE phase 3 studies: 100-week results with brolucizumab in patients with diabetic macular edema","volume":"260","author":"Wykoff","year":"2024","journal-title":"Am J Ophthalmol"},{"key":"R16-20260422","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1001\/jamaophthalmol.2021.4585","article-title":"Safety outcomes of brolucizumab in neovascular age-related macular degeneration: results from the IRIS registry and Komodo Healthcare Map","volume":"140","author":"Khanani","year":"2022","journal-title":"JAMA Ophthalmol"}],"container-title":["Indian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_1897_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T18:55:17Z","timestamp":1786647317000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_1897_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,28]]},"references-count":13,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/ijo.ijo_1897_24","relation":{},"ISSN":["0301-4738","1998-3689"],"issn-type":[{"value":"0301-4738","type":"print"},{"value":"1998-3689","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,28]]}}}